1,2,3,4-tetrahydro-6-methoxy-1-methyl-2-oxo-4-quinolineacetaldehyde | 125810-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,2,3,4-tetrahydro-6-methoxy-1-methyl-2-oxo-4-quinolineacetaldehyde
• 英文别名: 2-(6-methoxy-1-methyl-2-oxo-3,4-dihydroquinolin-4-yl)acetaldehyde
• CAS: 125810-78-8
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: LWTZTXKQZITVPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2,3,4-tetrahydro-6-methoxy-1-methyl-2-oxo-4-quinolineacetaldehyde 在 四丁基氟化铵 、 sodium 、 三溴化硼 、 sodium cyanoborohydride 、 lithium chloride 、 正丁醇 作用下， 以 甲醇 为溶剂， 生成 (8,10-dimethyl-8,10-diazatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-yl) N-methylcarbamate
  参考文献：
  名称：

  Synthesis and carbamoylation of 1,2,3,4,5,6-hexahydro-1,3-dimethyl-2,6-methano-1,3-benzodiazocin-8-ol: bridged analogues of physostigmine

  摘要：

  The synthesis and carbamoylation of 2,6-methano-1,3-benzodiazocin-8-ol is described. A one pot silyl-aryl ether to carbamate transformation was developed. The compounds are analogues of the cholinesterase inhibitor physostigmine.

  DOI：

  10.1016/0040-4039(92)88151-t
• 作为产物：
  描述：

  1,2,3,4-Tetrahydro-6-methoxy-3-(methoxycarbonyl)-2-oxo-4-quinoline acetic acid, methyl ester 在 吗啉 、 sodium hydride 、 二异丁基氢化铝 、 sodium chloride 作用下， 以 水 、 二甲基亚砜 、 甲苯 为溶剂， 生成 1,2,3,4-tetrahydro-6-methoxy-1-methyl-2-oxo-4-quinolineacetaldehyde
  参考文献：
  名称：

  Synthesis and carbamoylation of 1,2,3,4,5,6-hexahydro-1,3-dimethyl-2,6-methano-1,3-benzodiazocin-8-ol: bridged analogues of physostigmine

  摘要：

  The synthesis and carbamoylation of 2,6-methano-1,3-benzodiazocin-8-ol is described. A one pot silyl-aryl ether to carbamate transformation was developed. The compounds are analogues of the cholinesterase inhibitor physostigmine.

  DOI：

  10.1016/0040-4039(92)88151-t

文献信息

• 2,6-methano-1,3-benzodiazocine compounds which have useful
  申请人：Hoechst-Roussel Pharmaceuticals, Inc.

  公开号：US05010083A1

  公开（公告）日：1991-04-23

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  揭示了一种新型2,6-甲烷基-1,3-苯并二氮杂环化合物、中间体、其制备方法以及利用该化合物或其组合物缓解疼痛和缓解由于乙酰胆碱功能下降而表现为各种记忆功能障碍的方法，例如阿尔茨海默病。
• Process of preparing 2,6-methano-1,3-benzodiazocine compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05264575A1

  公开（公告）日：1993-11-23

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  本发明公开了一种新型的2,6-甲氧基-1,3-苯并二氮杂环化合物，以及其中间体和制备方法，还公开了利用这些化合物或组合物缓解疼痛和缓解由于胆碱能功能降低而表现为不同记忆功能障碍（例如阿尔茨海默病）的方法。
• 2,6-methano-1,3-benzodiazocine compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05097033A1

  公开（公告）日：1992-03-17

  Novel 2,6-methano-1,3-benzodiazocines, intermediates, processes for the preparation thereof, and methods for alleviating pain and for alleviating various memory dysfunctions characterized by a decreased cholinergic function, such as Alzheimer's disease, utilizing compounds or compositions thereof are disclosed.

  本发明涉及一种新型的2,6-甲基-1,3-苯并二氮杂环化合物、中间体、其制备方法以及利用其化合物或组合物缓解疼痛和缓解由乙酰胆碱能功能降低引起的各种记忆功能障碍，例如阿尔茨海默病的方法。
• 2,6-Methano-1,3-benzodiazocines, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0335292A2

  公开（公告）日：1989-10-04

  The present invention relates to compounds of the formula I wherein R¹ is hydrogen, loweralkyl, loweralkylcarbonyl, loweralkylaminocarbonyl, cycloalkylaminocarbonyl, loweralkoxycarbonyl, aryloxycarbonyl, or arylaminocarbonyl; R² and R³ are independently hydrogen, loweralkyl, cycloalkylloweralkyl, arylloweralkyl, or loweralkenyl; R⁴ and R⁵ are independently hydrogen or loweralkyl; Y is halogen, loweralkyl, nitro, amino, loweralkylcarbonylamino, arylcarbonylamino, formyl or loweralkylaminocarbonyl; and n is an integer having a value of zero or 1; the geometrical isomers, optical antipodes or pharmaceutically acceptable acid addition salts thereof, and to a process for their preparation. The compound have analgesic acetivities, and can, there­fore, be used as medicaments.

  本发明涉及式 I 的化合物 其中R¹是氢、低级烷基、低级烷基羰基、低级烷基氨基羰基、环烷基氨基羰基、低级烷氧基羰基、芳氧基羰基或芳基氨基羰基；R²和R³独立地是氢、低级烷基、环烷基低级烷基、芳基低级烷基或低级烯基；R⁴和R⁵独立地是氢或低级烷基；Y 是卤素、低级烷基、硝基、氨基、低级烷基羰基氨基、芳基羰基氨基、甲酰基或低级烷基氨基羰基；n 是数值为 0 或 1 的整数；其几何异构体、光学对映异构体或药学上可接受的酸加成盐，以及其制备方法。 这些化合物具有镇痛乙酰活性，因此可用作药物。
• US5010083A
  申请人：——

  公开号：US5010083A

  公开（公告）日：1991-04-23